Hepatitis B Group Education Program is a culturally targeted group education program funded by Gilead Sciences, provided culturally appropriate Hepatitis B education to African Immigrants residing in New York City. The group education program provided information that positively impacted participants’ knowledge about Hepatitis B screening and vaccination.
- Total Number of Programs since January 2016 = 12
- Total Number of Participants since January 2016 = 224
Hepatitis Outreach Network (HONE) is a viral hepatitis prevention, screening, and link to care study program focused on minority groups in New York, who are at high risk for chronic Hepatitis B (HBV) and chronic hepatitis C virus (HCV), diseases that have been linked to liver cancer.
- Screened for Hepatitis B & C since January 2016 = 257
- 5% had HCV; 8% had HBV; 57% were immune; 27% were negative; 3% were undetermined
Hepatitis C Education and Liver Screening (HEALS) is an outreach program, coordinated by the medical center’s Internal Medical Associates (IMA) primary care clinic, which provides free Hepatitis C testing and free Hepatitis C educational workshops for community based organizations, social services agencies and other community settings throughout New York City.
- Individuals screened for Hepatitis C in 2015 = 44
- 52 individuals had positive HCV antibody tests
All were offered free confirmatory testing following their antibody result. Eight declined this offer and did not pursue further care with our team. The remaining 44 accepted and completed a second confirmatory test and out of those 44, 30 were found to be chronically infected with Hepatitis C. Out of that 30, 17 accepted a referral to our clinic and were successfully connected to care.
This year our outreach team partnered with a total of 11 community agencies, as well as 4 programs within the Mount Sinai Health System (i.e. CARES, Mount Sinai Beth Israel, Mount Sinai West Addiction Institute’s Opioid Treatment Program and Mount Sinai Beth Israel LGBT Health). Of the 11 community organizations, 7 were new partnerships formed this grant year (Marks JCH, St. Mary’s and St. Antonio’s Church, SAPNA, SCAN NY, Station of Hope Prison Ministry, NYS Division of Parole and Safe Horizon). Our team also coordinated two events here at The Mount Sinai Hospital with the Division of Liver Diseases. All of these collaborative efforts resulted in a total of 90 testing and/or education sessions (2 events consisted of multiple sessions).
Project INSPIRE is a three year CMS funded project implementing care coordination for patients with HCV that has just concluded year 2 of its initiative. This is a multi-faceted program that is being led by the NYC Dept. of Health in conjunction with Mount Sinai and Montefiore medical centers. The information obtained from this project will be used to assess the effectiveness of care coordination in reducing barriers and avoidable costs throughout the treatment process. Enrolled patients are assigned a care coordinator who assists patients with scheduling appointments, following up on test results, aid in securing entitlement services, offer support and educational sessions in either individual or group based settings and help with obtaining prior authorization for HCV medications. Our care coordinators work with the Nurses, MA’s and Specialty Pharmacies taking on an interdisciplinary approach to HCV care.
- Enrollment through November 30th = 881 patients(65% are men and 38% identify as black, 37.2% as Hispanic or Latino). Of all enrolled patients, 87.2% have completed an intake assessment and 97.2% have completed a referral assessment. Nearly everyone (99.7%) has received some form of care coordination services. 97.7% of patients have completed their HCV medical evaluation. Of those who have received a full medical evaluation, 64.1% have begun treatment. Seventy-eight percent (211 patients) of those who started have completed. Sixty-six percent (139 patients) of those who completed have confirmed SVR 12 or 24. Fifty-nine percent of our patients who have been assessed are “high need”, indicating at least one (and frequently multiple) life areas requiring additional support, which we provide on an individualized basis. Of these high need patients, 84% have been identified as medically eligible for treatment. 71% of those confirmed as candidates for treatment have started treatment (270 of 381). Communication ratings on CAHPS survey are in the 90th percentile based on nationwide data, with 96% of respondents rating it top score.
STOMP- C Is a health initiative to evaluate the prevalence of Hepatitis C (HCV) positive baby-boomers (persons born from 1945-1965), receiving primary care at an urban tertiary care center. Annually, MHS serves over 240,000 patients, with approximately 96,000 patients in the HCV birth cohort. MHS’s Stomp-C project aims to implement and evaluate a HCV screening and link to care program for patients within the Baby Boomer birth cohort. Our innovative and multifaceted strategies include: Prompts in the electronic health records; Educational campaigns for providers; direct engagement of HCV treatment providers; Incorporation of patient navigators (2).
Below is our screening and linkage to care data to date:
- Screened 7,408 eligible patients for HCV (July 2014 – October 2016)
- 459 patients screened antibody (Ab) positive – 6.2%
- 383 RNA test conducted – 74%
- 240 patients were confirmed RNA positive – 3.3%
- 143 patients were linked to care (July 2014 – June 2016) – 54%